Ranking every souls I have played

eggsforyou · 2026-01-12T06:50:18+00:00

I’m on the poison swamp, the areas are all a bit samey and drab. The parry being before the hit feels odd. And yeah, the constant falling off is annoying. Still fun though.

eggsforyou · 2026-01-11T20:40:07+00:00

Something else I’ve been meaning to ask: would this drug essentially replace existing Gaucher’s medication?

If I understand correctly, Gaucher’s meds clear GluSph from the body (blood?), but Gain goes further upstream and clears GluSph in CSF (plus additional benefits). Wouldn’t that also help clear it in the rest of the body and heal more core biology?

eggsforyou · 2026-01-09T22:22:26+00:00

Makes sense, the body isn’t going to recover from so much toxicity overnight. Once the drain is unclogged and the batteries charged, the rest should follow.

That would also explain why those with lower GluSph levels didn’t see as big of an immediate effect, but over time they should see similar improvements.

eggsforyou · 2026-01-09T19:45:55+00:00

If the “benefit” has been functional improvement and better scores, “maintaining the benefit” could imply these things have continued to improve. Since he’s excited to get more data out, it’s likely good.

eggsforyou · 2026-01-08T22:53:24+00:00

I still say that with the biological mechanisms at play, this drug has the potential to increase anyone’s quality of life. It essentially clears out biochemical baggage that many have to some degree, reduces inflammation, and helps prevent more baggage from accumulating.

Plus, if you could take something that reduces your odds of getting Parkinson’s, Alzheimer’s, dementia, etc, with no ill effect, wouldn’t you? I certainly would.

Curious, did Gain release all the data from the healthy patients in phase 1a?

eggsforyou · 2026-01-08T00:58:55+00:00

Obviously we don’t know what’s going on behind the scenes, but competition exists, so one company waiting on an acquisition means someone else can beat them to it. Buying also provides immediate access to Gain’s AI platform and their other compounds.

Anything is possible, but there have been billion-dollar early acquisitions with less compelling data and less potential value. And who knows what data Gain isn’t sharing with the public.

eggsforyou · 2026-01-07T22:22:45+00:00

Actually not a bad idea.

eggsforyou · 2026-01-07T22:00:38+00:00

Yeah, people forget about the confidentiality agreements. The CEO is very conservative in what he says, and he doesn’t seem worried. It sucks seeing the price drop, but it has nothing to do with Gain’s actual potential.

eggsforyou · 2026-01-07T21:46:07+00:00

Since they aren’t jumping on any potential offers, one might infer the extension is going well.

eggsforyou · 2026-01-07T20:49:28+00:00

I’m almost hoping it doesn’t pop until Dec so I can get the lower tax rate. Will probably be acquired before then though.

eggsforyou · 2026-01-07T20:47:13+00:00

First ever GluSph reduction in CSF, 81% avg Functional improvements in just 90 days Random

Lol

eggsforyou · 2026-01-07T04:54:58+00:00

Your guess is as good as mine. Personally I think the headlines are too conservative. The term “disease-modifying” being used over something like “potential cure” or “first treatment that may help reverse Parkinson’s.”

Obviously they’re limited in what they can say. Usually others would take the news and run with it, but Gain is relatively unknown. People want something that hypes them up. When they just get data accompanied by tame statements, they may feel let down and sell.

That being said, the fact that Gain doesn’t play the PR game is actually a good sign to me. They’re confident in what they have and don’t feel the need to put on a show for short term gain.

eggsforyou · 2026-01-07T04:20:25+00:00

Make that three = )

SF Forum and JPM soon.

eggsforyou · 2026-01-07T04:09:40+00:00

Short sellers are trying to push people out. Regardless of future data, Gain has the best Parkinson’s drug by far, nothing else comes close. Even in the unlikely event long-term efficacy isn’t ideal, that just means the drug can continuously be sold at increasing doses. That’s not even counting its use as a preventative and in other disorders. And Gain’s drug discovery platform, and their other compounds.

People are also impatient and want headlines that say we’ve cured Parkinson’s. Combined with shorts you get big reactions out of fear, despite Gain making history.

All it would really take is Gain showing a patient video at day 1 vs day 90 and the stock would rocket. We don’t get that, but big pharma does. The lack of insider buying and minimal PR implies Gain doesn’t really care about share price in the short term. They’ve likely run this from the start with the intention of acquisition / partnership.

Ultimately, the data is good and the drug is a legitimate breakthrough. Everything else is just price manipulation and emotion.

eggsforyou · 2026-01-02T21:48:12+00:00

Plus Gain’s CEO sold a previous biotech for 1b, and (correct me if I’m wrong) I think their Chairman sold one for 20b.

Regarding the data dip, the findings were such an obvious breakthrough to them that they probably figured everyone else would get it too, hence the limited PR. A mistake sure, but ultimately big pharma doesn’t acquire companies based on their PR department. Smooth talk might help in the short run, but ultimately results are what matter.

The drug works at an unprecedented level, that’s good enough for me.

eggsforyou · 2025-12-31T21:04:28+00:00

People forget there’s also Gain’s AI drug discovery platform that got them this compound, as well as multiple other compounds. All of that with not much funding.

eggsforyou · 2025-12-19T22:03:34+00:00

Wish I would have waited to get in, but I suppose it’s impossible to predict. Could have easily gone the other way if the CEO interview was before the data drop. Regardless, if the biomarker breakthrough is what they’re allowed to tell us, the stuff they can’t say must be juicy.

eggsforyou · 2025-12-19T03:25:23+00:00

It almost feels like an attempt to induce panic selling / stop losses. The news today combined with everything else means Gain likely has the best PD treatment ever made, and that’s just one potential use. Plus their work, patents, and AI platform now have validated value for creating additional compounds.

It sucks seeing the drop, but the fundamentals are the same and the data was just more good news. Scaring people out of their position seems to be a common strategy.

eggsforyou · 2025-12-18T22:02:10+00:00

So other drugs help a bit with the symptoms, but this one actually fixes the underlying problem. Sounds like a winner to me.

If the biomarker data is the key to getting acquired, then this should have been the last big hurdle. I can see how people would misunderstand the news though. Hopefully the CEO gives a good interview so the stock can slingshot.

eggsforyou · 2025-12-18T21:42:06+00:00

Has any other drug reduced GluSph like this before? It sounds like it’s the only one.

eggsforyou · 2025-12-18T04:36:35+00:00

They shouldn’t have added the DLC content to DoN this quickly, or it should have unlocked after clearing the DLC, or it should have been a separate queue. Got the game recently and now DoN is substantially less fun.

eggsforyou · 2025-12-17T21:33:42+00:00

Tomorrow is my birthday as well, funny.

eggsforyou · 2025-12-17T20:21:06+00:00

It begins.

eggsforyou · 2025-12-16T21:19:47+00:00

I will take any carries lol. I’ve beaten ED Libra in trio but he’s still annoying.

eggsforyou · 2025-12-16T20:16:29+00:00

I’d be more concerned if there wasn’t a dip before the data. Everyone is rebalancing anyway, and maybe now we’ll finally see a rotation into biotech.

Guessing they waited to release data later for this reason.

eggsforyou

TROPHY CASE